| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Connect Biopharma Holdings Limited: Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 | 1 | GlobeNewswire (USA) | ||
| 23.12.25 | Connect Biopharma Holdings Ltd - 8-K, Current Report | 2 | SEC Filings | ||
| CONNECT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 14.11.25 | RedChip Companies, Inc.: Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 493 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies will air interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp. (OCTQB:BESS) on the RedChip... ► Artikel lesen | |
| 12.11.25 | Connect Biopharma GAAP EPS of -$0.31 | 1 | Seeking Alpha | ||
| 12.11.25 | Connect Biopharma Holdings Limited: Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update | 840 | GlobeNewswire (Europe) | - Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 - - New Drug Application for rademikibart... ► Artikel lesen | |
| 12.11.25 | Connect Biopharma Holdings Ltd - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Connect Biopharma Holdings Ltd - 8-K, Current Report | - | SEC Filings | ||
| 31.10.25 | BTIG stuft Connect Biopharma mit "Buy" ein - Potenzial bei Atemwegsmedikamenten | 1 | Investing.com Deutsch | ||
| 31.10.25 | Connect Biopharma stock initiated with Buy rating at BTIG on respiratory drug potential | 2 | Investing.com | ||
| 30.10.25 | RedChip Companies, Inc.: Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 | 384 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company)... ► Artikel lesen | |
| 30.09.25 | H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target | 9 | Investing.com | ||
| 29.09.25 | Connect Biopharma Holdings Limited: Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 13.08.25 | Connect Biopharma Holdings Limited: Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update | 305 | GlobeNewswire (Europe) | - Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations - - Presented positive data at ATS 2025 and EAACI 2025 supporting... ► Artikel lesen | |
| 21.07.25 | Connect Biopharma Holdings Limited: Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq | 348 | GlobeNewswire (Europe) | SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming... ► Artikel lesen | |
| 17.07.25 | Connect Biopharma Regains Nasdaq Compliance On Minimum Bid Price | 549 | AFX News | BEIJING (dpa-AFX) - Connect Biopharma Holdings Limited (CNTB), a clinical-stage biopharmaceutical company focused on inflammatory disease treatments, announced that it has regained compliance... ► Artikel lesen | |
| 17.07.25 | Connect Biopharma Holdings Limited: Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | 268 | GlobeNewswire (Europe) | SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming... ► Artikel lesen | |
| 20.05.25 | Connect Biopharma Announces Significant Findings Regarding Rademikibart | 441 | AFX News | BEIJING (dpa-AFX) - Connect Biopharma Holdings Limited (CNTB), Tuesday announced clinical and preclinical data regarding rademikibart for the treatment of patients with asthma or COPD experiencing... ► Artikel lesen | |
| 15.05.25 | Connect Biopharma Posts Wider Loss In Q1 | 382 | AFX News | BEIJING (dpa-AFX) - Connect Biopharma Holdings (CNTB) posted a net loss of $10.3 million, or $0.19 per share, for the three months ended March 31, 2025, compared with a net loss of $8.7 million... ► Artikel lesen | |
| 14.05.25 | Connect Biopharma Holdings Limited: Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD | 391 | GlobeNewswire (Europe) | - Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 - SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect... ► Artikel lesen | |
| 13.05.25 | Connect Biopharma Holdings Limited: Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma | 323 | GlobeNewswire (Europe) | - Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 - - On track to initiate similarly-designed Phase 2 study in patients with COPD imminently - SAN DIEGO, May 13, 2025... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 74,50 | -1,84 % | BioNTech nach den Turbulenzen: Was passiert jetzt mit dem Unternehmen? | Die Aktie von BioNTech wurde in den vergangenen Wochen ordentlich durchgeschüttelt. Insbesondere die Ankündigung, dass Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres die Gesellschaft verlassen... ► Artikel lesen | |
| EVOTEC | 4,304 | -1,62 % | EQS-News: Evotec SE: Just - Evotec Biologics und BARDA schließen Vereinbarung zur verbesserten Bioproduktion von Antikörpern gegen Ebola und verwandte Viren | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Just - Evotec Biologics und BARDA schließen Vereinbarung zur verbesserten Bioproduktion von Antikörpern gegen Ebola und verwandte... ► Artikel lesen | |
| BB BIOTECH | 46,050 | -2,54 % | Dividendenbekanntmachungen (23.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,94 CHF 1,0309 EUR AECON GROUP INC CA00762V1094 0,1925 CAD 0,1212 EUR AMPHENOL CORPORATION US0320951017 0... ► Artikel lesen | |
| MEDIGENE | 0,029 | -13,61 % | Medigene: Zurückziehung - 18.11.2025 | ||
| MODERNA | 43,975 | -5,45 % | MODERNA INC: Stabilität als strategisches Signal | ||
| VALNEVA | 2,830 | +1,36 % | Valneva-Aktie crasht brutal - die Hintergründe | Lange Gesichter bei den Aktionären von Valneva. Das Papier der europäischen Impfstoff-Hoffnung crasht zur Stunde um rund 40 Prozent. Für eine Enttäuschung sorgen die lang erwarteten Phase-3-Studiendaten... ► Artikel lesen | |
| AMGEN | 306,75 | -0,11 % | Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375 | ||
| NOVAVAX | 7,791 | -0,93 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 165,50 | -0,21 % | Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics | WESTON (dpa-AFX) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 39,600 | -3,88 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 656,20 | -0,12 % | Sanofi: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid | Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Approval in moderate-to-severe patients was based on pivotal study results... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - S-1, General form for registration of securities | ||
| BIONXT SOLUTIONS | 0,334 | -3,47 % | BioNxt tritt in die Kommerzialisierungsphase ein - mit globalem Patentschutz und US-Fast-Track-Strategie für seine sublinguale Wirkstoffplattform | VANCOUVER, BC / ACCESS Newswire /
24. März 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,210 | -4,98 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen |